Howard Trachtman

Pediatric Nephrology

160 E 32nd St Ste L3
New York, NY 10016

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 174 publications

SEISMIC: A multi-stakeholder summit addressing access issues in diagnosis and treatment of C3G nephropathy and IC-MPGN.

SEISMIC: A multi-stakeholder summit addressing access issues in diagnosis and treatment of C3G nephropathy and IC-MPGN.

Journal: Kidney international

Published: April 06, 2026

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.

Journal: Kidney international reports

Published: February 04, 2026

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Journal: Journal of the American Society of Nephrology : JASN

Published: January 21, 2026

Air pollution and disease progression among patients with primary glomerular disease: an expanded study with extended follow-up.

Air pollution and disease progression among patients with primary glomerular disease: an expanded study with extended follow-up.

Journal: Environmental health : a global access science source

Published: January 20, 2026

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.

Journal: Pediatric nephrology (Berlin, Germany)

Published: January 13, 2026

Terms of Engagement.

Terms of Engagement.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: December 10, 2025

A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies.

A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies.

Journal: Kidney international

Published: November 07, 2025

A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies.

A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies.

Journal: Kidney international

Published: November 07, 2025

The Use of Extrapolation to Promote Clinical Trials in Pediatric Nephrology.

The Use of Extrapolation to Promote Clinical Trials in Pediatric Nephrology.

Journal: Journal of the American Society of Nephrology : JASN

Published: September 05, 2025

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

Journal: Lancet (London, England)

Published: August 21, 2025

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: June 26, 2025

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design.

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design.

Journal: Glomerular diseases

Published: June 13, 2025

Showing 1-12 of 174

Last Updated: 09/26/2026